Important drug interactions between HIV drugs and encorafenib and dabrafenib
17 June 2026. Related: Early access, PK and drug interactions.
Early access
New guidelines on persistent low-level viral load in people living with HIV (2026)
12 June 2026. Related: Early access, Treatment strategies, Guidelines, Drug resistance.
Once-weekly oral islatravir/lenacapavir meets 48-week primary endpoint in phase 3 studies
9 June 2026. Related: Early access, Antiretrovirals.
UKHSA continues to recommend 4CMenB vaccine against gonorrhoea in gay men
9 June 2026. Related: Early access, Coinfections and complications, Vaccines and microbicides.
CHAI reports impact of cuts in HIV, CD4 and viral load testing, reduced PrEP: children fare worst
9 June 2026. Related: Early access, Treatment access, HIV prevention and transmission.
BHIVA 2026: Chemsex data, service needs and how health workers can help
1 June 2026. Related: Early access, Conference reports, HIV prevention and transmission, Injecting drug users, Activism & advocacy.
New study predicts that PrEP efficacy in men is driven by drug levels in cells: matching earlier results in women
12 May 2026. Related: Journal scan, Early access, HIV prevention and transmission.
Long-lived macrophages might explain non-suppressible low-level viraemia on ART
6 May 2026. Related: Early access, Treatment strategies, Virology, Drug resistance.
HIV rates in transgender people in Australia drops by 94% as PrEP access increases over 10 years
2 May 2026. Related: Journal scan, Early access, HIV prevention and transmission.
US FDA and Japan approve new once-daily oral HIV combination of doravirine/islatravir (IDVYNSO)
21 April 2026. Related: Early access, Antiretrovirals.
US CDC stops testing services for key infectious diseases: rabies, mpox, measles, EBV, SARS and others
8 April 2026. Related: Early access, Activism & advocacy.
Psilocybin is 6-fold more effective than nicotine patches to stop smoking in pilot US study with CBT
7 April 2026. Related: Journal scan, Early access.
Update on Gilead’s once-weekly oral HIV GS-1720 and GS-4182 studies
2 April 2026. Related: Early access, Antiretrovirals.
Two cases of severe hyperglycemia with injectable CAB/RPV-LA
5 March 2026. Related: Journal scan, Early access, Side effects.